Chammas & Marcheteau advises Damae Medical on €15 million Series B financing

"Chammas & Marcheteau advised Damae Medical on a €15 million Series B round led by Creadev, with participation from historic investors Kurma Partners, ISPB and BNP Paribas Développement. The financing will accelerate deployment of Damae’s deepLive™ non‑invasive AI imaging devices and further develop its software solutions."

Chammas & Marcheteau advised Damae Medical in connection with its €15 million Series B financing, which was led by Creadev alongside historic investors Kurma Partners, ISPB and BNP Paribas Développement. The transaction consists of a €15 million Series B capital raise led by Creadev with continued participation from Damae Medical’s existing investors Kurma Partners, ISPB and BNP Paribas Développement. The funds will be used to accelerate the commercial deployment of the company’s technology and to continue enhancing its software solutions. Founded in 2014, Damae Medical develops non‑invasive imaging devices designed to help dermatologists improve diagnosis, notably for the screening of skin cancers. More than 120 deepLive™ systems, which use real‑time artificial intelligence, have been deployed to date. The technology is already in use in around fifteen countries across Europe, the United States and Australia, and the new financing is intended to support further international roll‑out and product development. Chammas & Marcheteau represented Damae Medical with a team composed by: Nicolas Lecocq (partner) and Sandie Dion (lawyer).

Chammas & Marcheteau advises Damae Medical on €15 million Series B financing

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads